SynthesisBMC musculoskeletal disorders2020
Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis.
Synthesis in BMC musculoskeletal disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- The Effect of Denosumab and Risk Factors for Recurrence in Spinal Giant Cell Tumors: A Systematic Review and Meta-Analysis.Yonsei medical journal · 2022Pooled it
- JMT103 versus Non-Denosumab or Denosumab Treatment in Chinese Patients with Unresectable or Surgically Challenging Giant Cell Tumor of Bone: A Propensity Score-Matched Comparison.Cancer medicine · 2025Observational
- A Multicenter Study by the DENO Research Group on the Use of Denosumab in Giant-Cell Tumors of the Bone.Journal of clinical medicine · 2025Article
- Clinical Outcomes of CurettageRevista brasileira de ortopedia · 2024Article
- Current indications for denosumab in benign bone tumours.EFORT open reviews · 2023Review
- Management of a rare mandibular giant cell tumor of bone by neoadjuvant denosumab therapy and surgery: A 4-year follow-up case report.International journal of surgery case reports · 2023Article
- Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone.Cancers · 2023Article
- Preoperative denosumab treatment in patients with giant cell bone tumors in limbs: A retrospective study using propensity score matching.Cancer medicine · 2023Article
- Primary Cooperative Application of a LARS® Tube and 3D-Printed Prosthesis for Reconstruction of the Distal Radius after en bloc Resection of Giant Cell Tumor of Bone: A Comparative Retrospective Study.Orthopaedic surgery · 2023Article
- Current therapies and future prospective for locally aggressive mesenchymal tumors.Frontiers in oncology · 2023Review
- Review
- Article
- Role of denosumab before resection and reconstruction in giant cell tumors of bone: a single-centered retrospective cohort study.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2022Article
- Study of imaging changes following preoperative denosumab for giant cell tumor of bone.Journal of bone oncology · 2022Article
- The Activation of PDGFRβ on Mononuclear Stromal/Tumor Cells in Giant Cell Tumor of Bone After Denosumab Treatment. An Immunohistochemical Study of Five Cases.Pathology oncology research : POR · 2022Article
- Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment.Scientific reports · 2021Article
- The impact of curettage technique on local control in giant cell tumour of bone.International orthopaedics · 2021Review
- The use of denosumab in the setting of acute pathological fracture through giant cell tumour of bone.World journal of surgical oncology · 2021Article
- Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls.Frontiers in oncology · 2020Review
- Giant Cell Tumor of the Cervical Axis Treated With Anterior-Posterior Surgery and Denosumab: A Ten-year Follow-up Case Report.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundIn 2013, denosumab was introduced as peri-operative adjuvant treatment for giant cell tumor (GCT) of bone as it inhibits osteoclast activity. It is suggested that denosumab relives pain, facilitate curettage in lesions requiring resection initially. However, controversy remains whether denosumab increases the risk of local recurrence after surgery.
methodsMedline, Embase and the Cochrane Library were comprehensively searched in June 2019 to identify studies investigating the clinical outcome of GCT of bone with and without peri-operative denosumab after surgery. Data were gathered and a meta-analysis was conducted.
resultTen studies with 1082 cases (169 in denosumab group, 913 in control group) were included. Overall, denosumab was associated with significantly higher risk of recurrence(P < 0.02) and inferior 5 year recurrence free survival(P = 0.000). Denosumab and curettage has a relatively higher risk of recurrence comparing to curettage alone(P = 0.07). The risk of recurrence is not significantly increased if denosumab was administered both preoperatively and postoperatively(P = 0.24).
conclusionAdministration of denosumab is associated with increased risk of recurrence due to a variety of reasons, though it is proven effective in relieving pain, enabling curettage and improved functional outcome. Post-operative denosumab is recommended as it continuously suppress/eliminate residue tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.